Journal
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Volume 63, Issue 7, Pages 653-656Publisher
AMER SOC HEALTH-SYSTEM PHARMACISTS
DOI: 10.2146/ajhp050355
Keywords
blood levels; ciprofloxacin hydrochloride; drug interactions; drugs, availability; excretion; gastrointestinal drugs; omeprazole; pharmacokinetics; quinolones; sustained-action medications; urine levels
Categories
Ask authors/readers for more resources
Purpose. The effect of omeprazole on the bioavailability and urinary exposure of the Depomed formulation of extended-release (ER) ciprofloxacin was studied. Methods. A two-way crossover study was conducted in healthy subjects. Subjects received either a single dose of ER ciprofloxacin 1000 mg or a single dose of ER ciprofloxacin 1000 mg following three days of treatment with omeprazole 40 mg. Blood and urine samples were collected over 36 hours, and ciprofloxacin concentrations were determined using high-performance liquid chromatography. Results. Twenty-seven subjects (16 men, 11 women) received both treatments. The mean maximum concentration, mean area under the plasma-versus-concentration curve, and mean amount of ciprofloxacin excreted in urine were similar between the two treatments and met strict bioequivalence criteria. Conclusion. Omeprazole did not affect the plasma or urinary pharmacokinetics of an oral ER formulation of ciprofloxacin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available